Advances In Prostate Cancer Research

Preparing to load PDF file. please wait...

0 of 0
Advances In Prostate Cancer Research

Transcript Of Advances In Prostate Cancer Research

POSTER SESSION A Sunday, Jan. 19 • 5:30-7:30 p.m. In board assignment order
 (A01) Use of a decision aid for patients diagnosed with castration resistant prostate cancer, Randy A. Jones.
 (A02, PR01) Monitoring copy number aberration dynamics in sequential plasma samples from castration-resistant prostate cancer (CRPC) patients, Gerhardt Attard.
 (A03) Complementarity of genomic instability, heterogeneity, and tumor microenvironment indices for predicting prostate cancer recurrence, Paul C. Boutros.
 (A04) The CCP score: A novel genetic test for prostate cancer prognosis, Steven Stone.  (A05) Sequential monitoring of circulating tumor cells (CTCs) using the Epic Sciences
platform in castration-resistant prostate cancer (CRPC) patients treated with AR targeting therapeutics (ATT), Roberta Ferraldeschi.  (A06) Evaluation of a Genomic Classifier (Decipher) in subsets of primary tumors with common prostate cancer genomic alterations, Mohammed Alshalafa.  (A07) Integration of the Decipher genomic classifier with SChLAP1 long noncoding RNA for improved prediction of metastasis post radical prostatectomy, Felix Feng.  (A08) Validation of a genomic classifier for predicting clinical progression following postoperative radiation therapy in high-risk prostate cancer, Robert B. Den.  (A09) Improving risk stratification for prostate cancer using the long noncoding RNA SChLAP1, a novel biomarker of aggressive disease, Felix Y. Feng.  (A10) MicroRNA profiles as predictors of aggressive prostate cancer, Mireia Olivan.  (A11, PR02) Frequency and characterization of circulating tumor cell (CTC) populations in metastatic castration-resistant prostate cancer (mCRPC), Ryan Dittamore.  (A12) Genetic variation in the IL-6 response element of SPINK1 promoter and prostate cancer in men of African descent, Danyelle Winchester.  (A13) Dietary and lifestyle factors and risk of progression in contemporary active surveillance patients, Bruce J. Trock.  (A14) Modification of IGF/insulin signaling in prostate cancer survival by TMPRSS2:ERG fusion, Thomas U. Ahearn.  (A15, PR03) Development and validation of a lifestyle score for prevention of lethal prostate cancer, Stacey A. Kenfield.

 (A16) Meat, fish, poultry, and egg intake at diagnosis and risk of prostate cancer progression, Kathryn M. Wilson.
 (A17) BRCA1single nucleotide polymorphisms (SNPs) may help identify patients at risk for lethal prostate cancer or recurrence after treatment with radiation therapy, Irene Shui.
 (A18) Association of obesity and diabetes with clinical characteristics and recurrence from prostate cancer in an ethnically-diverse population, Ilir Agalliu.
 (A19) The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer, Rebecca E. Graff.
 (A20) A novel gene expression signature predictive of clinical recurrence after radical prostatectomy in early-stage prostate cancer patients, Ahva Shahabi.
 (A21, PR04) Urinary melatonin levels, sleep disruption, and risk of prostate cancer, Sarah C. Markt.
 (A22) Obesity, IGF-1 receptor, and prostate cancer survival, Ericka Noonan.  (A23) Physical activity and tumor vessel morphology among men with prostate cancer, Erin
Van Blarigan.  (A24) The impact of body mass index on treatment recommendations for patients with low-
intermediate risk prostate cancer. Kosj Yamoah.  (A25) Molecular differences in transition zone and peripheral zone tumors, Jennifer A. Sinnott.  (A26) Immediate vs. delayed initiation of androgen deprivation therapy on PSA-relapsed
prostate cancer, Xabier Garcia-Albeniz.  (A27) Prevalence of undetected prostate cancer: Implications for epidemiology in the PSA-
Era, Jaquelyn L. Jahn.  (A28) Nonseasonal-SAD and APO E4 as risk factors for prostate cancer, Tim R. D. Oliver.  (A29) Inhibition of lactate production for modulating prostate cancer aggressiveness and
metastatic potential, Pankaj Seth.  (A30) CYP3A5 regulates prostate cancer growth by facilitating nuclear translocation of AR,
Ranjana Mitra.  (A31) YAP1 Is a key component of the AR signaling complexes in prostate cancer cells, Bekir
Cinar.  (A32) Androgen receptor non-nuclear regulation of prostate tumor cell invasion through
Matriptase and Src signaling, Jelani C. Zarif.  (A33) Influence of tumor microenvironment on the expression of tumor metastasis suppressor
KISS1 in prostate cancer, Honghe Wang.  (A35) New insights into the regulation of the androgen receptor by PMEPA1/NEDD4-1 in
prostate cancer, Hua Li.  (A36) Two independent functional screens identify miRNAs that regulate the AR signaling axis
in prostate cancer, Binod Kumar.  (A37) Evaluation of ERG responsive proteome in prostate cancer cells, Shyh-Han Tan.

 (A38) NOTCH transcription factors as common targets of ERG in diverse tumor cell types, Ahmed A. Mohamed.
 (A39) Functional characterization of androgen receptor ubiquitylation sites in prostate cancer cells, Ziyang Yu.
 (A40) Expression of ING3 associated with prostate cancer progression, Amal Almami.  (A41) SNPs that modulate the TMPRSS2 androgen responsiveness, Frank Claessens.  (A42) ADRB2 down-regulation affects glucuronidation activity and improves androgen
receptor sensitivity in LNCaP cells, Peder Rustøen Braadland.  (A43) Metformin inhibits the proliferation of human prostate cancer PC-3 cells via down-
regulation of the insulin-like growth factor 1 receptor, Kato Haruo.  (A44) Analysis of domains required for the oncogenic function of ETS transcription factors in
prostate cells, Vivekananda Kedage.  (A45) Monitoring androgen receptor dynamics at the single cell level, Katherin Patsch.  (A46) Loss-of-function mutations in RFC1 and TET1 in primary prostate cancer, Lien Spans.  (A47) Insulin increases migration and invasion in androgen deprived prostate cancer cells,
Jennifer H. Gunter.  (A48) PTEN loss together with ERG overexpression correlates with shorter survival after
radical prostatectomy, Andrew Erickson.  (A49) p38-MAPK regulation of Notch signaling is required for normal prostate epithelial
differentiation, Sander B. Frank.  (A50) Prostate cancer genetic-susceptibility locus on chromosome 20q13 is androgen
receptor-regulated and amplified in metastatic tumors, David P. Labbé.  (A51) AXIN2 predicts prostate cancer recurrence and promotes an invasive, cancer stem-like
phenotype, Brian Hu.  (A52) HDAC inhibition sensitizes prostate cancer cells to PARP inhibitor through
downregulation of DNA repair proteins, Olivia S. Chao.  (A53) Global transcriptome sequencing of ethnically diverse formalin-fixed patient samples in
prostate cancer identifies biomarkers of recurrence, Carlos S. Moreno.  (A54, PR06) Coordinate induction of autophagy and apoptosis by wildtype p53 in prostate
cancer cells, Chris Albanese.  (A55) Tumor suppressive roles of FoxA1 in castration-resistant prostate cancer, Jindan Yu.  (A56, PR07) Patient-specific kinase activation patterns in lethal metastatic castration resistant
prostate cancer, Justin M. Drake.  (A57) Modeling genetic changes of LnCAP in the mouse: The role of Abi1 in prostate tumor
progression in the absence of PTEN, Leszek Kotula.  (A58) Integrated analysis of epigenomic and genomic changes regulated by DNA methylation
dependent mechanisms provides potential novel biomarkers for prostate cancer, Nicole M.A. White-Habeeb.

 (A59) Androgen receptor directly suppresses the expression of a subset of genes mediating DNA synthesis, Changmeng Cai.
 (A60) A novel metastatic mouse model of advanced prostate cancer driven by the c-Myc and KLF6-SV1 oncogenes, Sudeh Izadmehr.
 (A61) Targeting MYC-driven growth and proliferation in prostate cancer, Luc Furic.  (A62) Role of hepatoma up-regulated protein (HURP) in prostate cancer tumorigenesis and
resistance to therapy, Christian R. Gomez.  (A63) SOCS3 deficiency in myeloid cells promotes prostate tumor development, Etty (Tika) N.
Benveniste.  (A64) Combining ex vivo culture and tumorgraft models for the benign and malignant human
prostate, Sophia L. Maund.  (A65) Inhibition of radiation induced CXCL8 signaling sensitizes PTEN-deficient prostate
carcinoma tumors to ionizing radiation, David J. Waugh.  (A66) Genetically modifying Apc and Smad4 in the murine prostate incudes HGPIN and
carcinoma, Kenneth C. Valkenburg.  (A67) Novel animal models to study dormant prostate and prostate cancer cells, Dingxiao
Zhang.  (A68) Rad9 controls integrin beta1 expression and mediates radiosensitivity of prostate
cancer cells, Constantinos G. Broustas.  (A69) Lyn kinase induces mesenchymal phenotype by stabilizing Slug, Daksh Thaper.  (A70) The miR-409-5p in the imprinted and developmentally regulated DLK1-DIO3 cluster
promotes tumorigenesis, epithelial to mesenchymal transition and bone metastasis in prostate cancer, Murali Gururajan.  (A71) Persistent androgen ablation promotes enhanced neuroendocrine features in Ptendeficient prostate cancer, David J. Mulholland.  (A72) Cabozantinib attenuates CXCL8-driven macrophage-dependent migration and invasion of PTEN-deficient prostate cancer, David J. Waugh.

POSTER SESSION B Monday, Jan. 20 • 1-3 p.m. In board assignment order
 (B01) Green tea and quercetin sensitized castration-resistant prostate cancer cells to docetaxel treatment, Piwen Wang.
 (B02, PR08) A phase Ib study of BKM120 combined with abiraterone acetate for castrateresistant, metastatic prostate cancer, Akash Patnaik.
 (B03) Galeterone overcomes second-generation antiandrogen resistance in vitro, Nader Al Nakouzi.
 (B04) Effect of a selective CYP17-lysase inhibitor, VT464, on androgen receptor signaling in prostate cancer cells and on tumor growth of a patient-derived castrate-resistant prostate cancer xenograft, Sankar N. Maity.
 (B05) Farnesoid-X-receptor: A novel pharmacological target for the treatment of prostate cancer, Louis Gauthier-Landry.
 (B07) Sintokamide A inhibits castration resistant prostate cancer by targeting the aminoterminus of the androgen receptor, Carmen Adriana Banuelos.
 (B08) Virotherapy of canine tumor xenografts with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody, Sandeep S. Patil.
 (B09) JAK2 inhibition as a novel treatment for castration resistant prostate cancer (CRPC), Jacob Kach.
 (B10) Inhibition of prostate cancer bone metastases by a novel Tiam1 inhibitor, Emmanuelle J. Meuillet.
 (B11) Targeting integrin alpha6 stimulates curative-type bone metastasis lesions in a xenograft model, Terry H. Landowski.
 (B12) Potential impact of ERG-typing on the biology and biomarker utility in the context of ethnic differences of prostate cancer, Albert Dobi.
 (B13) TMPRSS2-ERG fusions regulate intratumoral androgen production in prostate cancer cells, Sreenivasa R. Chinni.
 (B14) Co-targeting of the androgen receptor and Hsp90 prevents nuclear localization of the androgen receptor and induction of the heat shock response in prostate cancer cells, Margaret M. Centenera.
 (B16) Chromosome 8 alterations and PTEN loss in Gleason grade 3 cores predict the presence of unsampled grade 4 tumor: Implications for active surveillance, Bruce J. Trock.

 (B17) NuSAP is regulated by RB1 and modulates prostate cancer progression, Catherine A. Gordon.
 (B18) Targeting FOXM1 reduces the viability of Enzalutamide resistant prostate cancer cells, Kirsi Ketola.
 (B19) In vivo role of miR-32 in prostate cancer, Leena Latonen.  (B20, PR09) Prostate cancer originating in basal cells progresses to adenocarcinoma
propagated by luminal-like cells, Tanya Stoyanova.  (B21) ETS and AP-1 transcription factors integrate RAS/ERK and PI3K/AKT signaling to
regulate prostate cell migration, Peter C. Hollenhorst.  (B22) Sox2 is an androgen receptor-repressed gene that promotes castration-resistant
prostate cancer, Steven Kregel.  (B23) CD133 expression marks rapidly proliferating cells in human prostate cancer, Edwin E.
Reyes.  (B24) Delineation of the biological link between the ERG splice variant, ERG8, and its
prognostic features, Anshu Rastogi.  (B25) Use of short tandem repeat profiling and DNA based mycoplasma analysis for
authentication of human and mouse cell Llnes, Michael L. Baird.  (B26) Single-CTC whole genome sequencing in prostate cancer, Yi-Tsung Lu.  (B27) Quantitative in-depth proteomic profiling of FFPE prostate cancer tissues, Diego
Iglesias-Gato.  (B28) Redox Factor-1 regulates drug resistance in prostate cancer cells via survival protein
induction, Travis J. Jerde.  (B29) Targeting enzalutamide resistance with combination AKT and AR pathway inhibition,
Paul Toren.  (B30) Transcriptome-wide analysis of prostate biomarkers in matching tumor and non-
neoplastic samples from biopsy and radical prostatectomy, Jeffry P. Simko.  (B31) Global alternative splicing detection pipeline (I-GRASP) for analysis of splicing
signatures in prostate cancer, Anna Lapuk.  (B32) The tyrphostin, NT157, potently suppresses insulin receptor substrates and induces
apoptosis in prostate cancer cells, Michael E. Cox.  (B33) Interleukin-15 inhibits prostate cancer cell migration, Magaly Martinez-Ferrer.  (B34) Epigenetic regulation of MST1/STK4 expression by a cooperative MYC and EZH2
signaling in prostate cancer cells, Bekir Cinar.  (B35, PR10) CpG-STAT3 siRNA for therapy of castration-resistant prostate cancers, Marcin
Kortylewski.  (B36) Altered periprostatic adipose tissue composition may predict prostate cancer
aggressiveness, Palamadai N. Venkatasubramanian.  (B38) PARP inhibitor nanotherapy and radiosensitization for prostate cancer, Srinivas Sridhar.

 (B39) Smart brachytherapy spacers eluting nanoencapsulated radiosensitizers for chemoradiation therapy of prostate cancer, Srinivas Sridhar.
 (B40) Helsinki Urological Biobank (HUB): A new-generation integrated biobank for facilitating precision medicine and translational research in urological cancers, Tuomas Mirtti.
 (B41) Cross-species analysis of genome-wide regulatory networks identifies a synergistic dependency between FOXM1 and CENPF that drives prostate cancer malignancy, Alvaro Aytes.
 (B42) Identification of SNPs associated with prostate cancer risk that are linked in trans to RNA expression changes in tumor-adjacent stroma, Xin Chen.
 (B43) Androgen receptor independent acquired mechanisms of resistance to enzalutamide in castration-resistant prostate cancer, Steven Kregel.
 (B44, PR11) Immune evasion strategies of neuroendocrine-like enzalutamide resistant prostate cancer, Jennifer L. Bishop.
 (B45) Targeted sequencing of circulating tumor cells (CTCs) in hormone-sensitive prostate cancer, Brian Hu.
 (B46) An innate developmental lineage plasticity of prostate cancer cells revealed by a new cell culture paradigm, Ralph Buttyan.
 (B47) Chronic use of NSAIDs and/or statins does not impact longitudinal PSA or PSA velocity in men at high risk for prostate cancer, Steven P. Stratton.
 (B48) Serum fucosylated haptoglobin is a novel type of prognostic biomarker predicting prostate cancer with Gleason score 7 or more, Kazutoshi Fujita.
 (B50) How diet and exercise can re-tune metabolism to prevent aggressive prostate cancer, Richard Mithen.
 (B51) Circulating vitamin D and inflammation in lethal prostate cancer, Julia O. Udesky.  (B52) A laboratory metabolomics assay, Prostarix, to stratify men at risk for prostate cancer
prior to prostate biopsy, Jonathan McDunn.  (B53) A molecular portrait of Gleason 7 prostate cancer, Michael Fraser.  (B54) Regulation of the cell cycle on progression in PC-3 human prostate cells treatment by
medicinal plant, Gronwell seed, Harukuni Tokuda.  (B55) The effects of PSMA on prostate carcinogenesis is modifiable by dietary folate and
glutamate carboxypeptidase II inhibitors, Dean J. Bacich.  (B56) ERG suppresses ANXA2 expression and function in prostate cancer and ERG and
ANXA2 expression patterns correlates with tumor differentiation, Nicholas B. Griner.  (B57, PR12) Mechanisms of clonal progression from Gleason 3 to Gleason 4 prostate cancer,
Adam G. Sowalsky.  (B58) Androgen resistance in prostate cancer is associated with an enrichment of stem-like
cells, Lisa Y. Wu.

 (B59) Integrative sequencing reveals alterations in untreated and castration resistant prostate cancer, Matti Annala.
 (B60) Low systemic testosterone levels induce androgen maintenance and changes in androgen receptor signaling in benign rodent prostate tissue, Jeremy O. Jones.
 (B61) Coordinate loss of CHD1 and MAP3K7 promotes aggressive prostate cancer, Leah Rider.
 (B62) Castrate resistant growth in the bone niche of novel patient-derived xenograft models of bone metastatic prostate cancer, Christina A.M. Jamieson.
 (B63) The vitamin K cycle modulates androgen receptor activity differently in benign and cancerous prostate cells, Ben Yi Tew.
 (B64) Intensive androgen deprivation therapy compensatorily activates PLZF-repressed oncogenic circuitry that reprograms the residual prostate cancer, Chen-Lin Hsieh.
 (B65) Castration resistance to metastasis: Crucial role of neogenin in prostate tumorigenesis, Goutam Chakraborty.
 (B66) In vivo quantitative phosphoproteomic profiling identifies PAK2 as a regulator of castration resistant prostate cancer growth, Amilcar Flores-Morales.
 (B67) Ron receptor signaling promotes obesity-induced prostate tumor growth and metastatic dissemination, Nicholas E. Brown.
 (B68) SRC family kinase FYN promotes MET tyrosine kinase activation, epithelial to mesenchymal transition and metastasis in human prostate cancer, Murali Gururajan.
 (B69) HGFL promotes prostate tumorigenesis in a murine model of prostate cancer, Juozas Vasiliauskas.
 (B70) Myc and Pten govern a prostate epithelial differentiation program involving ING4; Disruption of which is necessary for human prostate cancer development, Cindy K. Miranti.
Prostate CancerProstate Cancer CellsAdvancesRiskAndrogen Receptor